The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Chelating Activity of Advanced Glycation End-product Inhibitors
Open accessAbstract
The advanced glycation end-product (AGE) hypothesis proposes that accelerated chemical modification of proteins by glucose during hyperglycemia contributes to the pathogenesis of diabetic complications. The two most commonly measured AGEs, N(epsilon)-(carboxymethyl)lysine and pentosidine, are glycoxidation products, formed from glucose by sequential glycation and autoxidation reactions. Although several compounds have been developed as AGE inhibitors and are being tested in animal models of diabetes and in clinical trials, the mechanism of action of these inhibitors is poorly understood. In general, they are thought to function as nucleophilic traps for reactive carbonyl intermediates in the formation of AGEs; however alternative mechanisms of actions, such as chelation, have not been rigorously examined. To distinguish between the carbonyl trapping and antioxidant activity of AGE inhibitors, we have measured the chelating activity of the inhibitors by determining the concentration required for 50% inhibition of the rate of copper-catalyzed autoxidation of ascorbic acid in phosphate buffer. All AGE inhibitors studied were chelators of copper, as measured by inhibition of metal-catalyzed autoxidation of ascorbate. Apparent binding constants for copper ranged from approximately 2 mm for aminoguanidine and pyridoxamine, to 10-100 microm for carnosine, phenazinediamine, OPB-9195 and tenilsetam. The AGE-breakers, phenacylthiazolium and phenacyldimethylthiazolium bromide, and their hydrolysis products, were among the most potent inhibitors of ascorbate oxidation. We conclude that, at millimolar concentrations of AGE inhibitors used in many in vitro studies, inhibition of AGE formation results primarily from the chelating or antioxidant activity of the AGE inhibitors, rather than their carbonyl trapping activity. Further, at therapeutic concentrations, the chelating activity of AGE inhibitors and AGE-breakers may contribute to their inhibition of AGE formation and protection against development of diabetic complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441
Self-citationAminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking
Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., & Cerami, A. (1986) · Science · doi:10.1126/science.3487117 · Cited by 1,146
Protein glycation and oxidative stress in diabetes mellitus and ageing
Wolff, S. P., Jiang, Z. Y., & Hunt, J. V. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90040-a · Cited by 883
Glomb, M. A., & Monnier, V. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.17.10017 · Cited by 576
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
Vasan, S., Zhang, X., Zhang, X., Kapurniotu, A., Bernhagen, J., Teichberg, S., Basgen, J., Wagle, D., Shih, D., Terlecky, I., et al. (1996) · Nature · doi:10.1038/382275a0 · Cited by 466
Fu, M.-X., Wells-Knecht, K. J., Blackledge, J. A., Lyons, T. J., Thorpe, S. R., & Baynes, J. W. (1994) · Diabetes · doi:10.2337/diab.43.5.676 · Cited by 464
Self-citationBreakers of advanced glycation end products restore large artery properties in experimental diabetes
Wolffenbuttel, B. H. R., Boulanger, C. M., Crijns, F. R. L., Huijberts, M. S. P., Poitevin, P., Swennen, G. N. M., Vasan, S., Egan, J. J., Ulrich, P., Cerami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4630 · Cited by 434
Carnosine: Its properties, functions and potential therapeutic applications
Quinn, P. J., Boldyrev, A. A., & Formazuyk, V. E. (1992) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(92)90006-l · Cited by 306
In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs)
Booth, A. A., Khalifah, R. G., Todd, P., & Hudson, B. G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5430 · Cited by 286
Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging
Thorpe, S. R., & Baynes, J. W. (1996) · Drugs & Aging · doi:10.2165/00002512-199609020-00001 · Cited by 285
Self-citation
Cited by
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150
“Due to the involvement of oxidants and metals, such as iron and cooper in the formation of AGEs, the search for antioxidative and chelating nutrients is of increasing interest [42].”
BackgroundCopper, oxidative stress, and human health
Uriu-Adams, J. Y., & Keen, C. L. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.07.015 · Cited by 975
Diabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts
Thornalley, P. J. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.013 · Cited by 682
Negre‐Salvayre, A., Coatrieux, C., Ingueneau, C., & Salvayre, R. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707395 · Cited by 641
Advanced glycation end products: Key players in skin aging?
Gkogkolou, P., & Böhm, M. (2012) · Dermato-Endocrinology · doi:10.4161/derm.22028 · Cited by 584
Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease
Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., & Münch, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.016 · Cited by 524
Advanced glycation end products in the pathogenesis of chronic kidney disease
Rabbani, N., & Thornalley, P. J. (2018) · Kidney International · doi:10.1016/j.kint.2017.11.034 · Cited by 387
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
Degenhardt, T. P., Alderson, N. L., Arrington, D. D., Beattie, R. J., Basgen, J. M., Steffes, M. W., Thorpe, S. R., & Baynes, J. W. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00207.x · Cited by 378
Self-citationAdvanced glycation end-products and the progress of diabetic vascular complications.
Jakuš, V, & Rietbrock, N. (2004) · Physiological Research · doi:10.33549/physiolres.930430 · Cited by 341
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Novel inhibitors of advanced glycation endproducts
Rahbar, S., & Figarola, J. L. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.009 · Cited by 329
Inhibition of advanced glycation endproduct formation by foodstuffs
Wu, C.-H., Huang, S.-M., Lin, J.-A., & Yen, G.-C. (2011) · Food & Function · doi:10.1039/c1fo10026b · Cited by 328
Miyata, T., van Ypersele de Strihou, C., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., Ishikawa, N., Nangaku, M., & Kurokawa, K. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032418.67267.f2 · Cited by 290
Intervention strategies to inhibit protein carbonylation by lipoxidation‐derived reactive carbonyls
Aldini, G., Dalle‐Donne, I., Facino, R. M., Milzani, A., & Carini, M. (2007) · Medicinal Research Reviews · doi:10.1002/med.20073 · Cited by 289
Quercetin Inhibits Advanced Glycation End Product Formation by Trapping Methylglyoxal and Glyoxal
Li, X., Zheng, T., Sang, S., & Lv, L. (2014) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf504132x · Cited by 288
Molecular Basis of Arterial Stiffening: Role of Glycation – A Mini-Review
Sell, D. R., & Monnier, V. M. (2012) · Gerontology · doi:10.1159/000334668 · Cited by 282
Janus, A., Szahidewicz-Krupska, E., Mazur, G., & Doroszko, A. (2016) · Mediators of Inflammation · doi:10.1155/2016/3634948 · Cited by 271
Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases
Reddy, V. P., & Beyaz, A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.016 · Cited by 266
Intervention against the Maillard reaction in vivo
Monnier, V. M. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.014 · Cited by 196
Lipoxidation in cardiovascular diseases
Gianazza, E., Brioschi, M., Fernandez, A. M., & Banfi, C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101119 · Cited by 152
Mehta, R., Shangari, N., & O'Brien, P. J. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200600190 · Cited by 42
Metadata
- Authors
- Price, D. L., Rhett, P. M., Thorpe, S. R., & Baynes, J. W.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 276
- Issue
- 52
- Pages
- 48967-48972
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2082865005
- Cited by
- 308
- References
- 41
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.